Yaney Alexander, Stevens Andrew, Monk Paul, Martin Douglas, Diaz Dayssy A, Wang Shang-Jui
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
College of Medicine, The Ohio State University, Columbus, OH, United States.
Front Oncol. 2022 Jun 8;12:932637. doi: 10.3389/fonc.2022.932637. eCollection 2022.
Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of biochemical failure. No strict definition exists for OD, with historical and ongoing studies utilizing diverse criteria. There is mounting evidence from many different malignancies that patients with OD have improved outcomes compared to their widely metastatic counterparts. As such, treatment intensification of those with OD or oligoprogressive disease has become an area of intense interest and study. This article will review the biology, evidence and controversy behind the treatment of oligometastatic, oligorecurrent and oligoprogressive prostate cancer.
在全球范围内,前列腺癌是影响男性的最常见恶性肿瘤之一。随着先进分子成像技术的出现,越来越多的男性在初次诊断时或生化复发时被发现患有寡转移疾病(OD)。目前尚无OD的严格定义,历史研究和正在进行的研究使用了不同的标准。来自许多不同恶性肿瘤的证据越来越多,表明与广泛转移的患者相比,OD患者的预后有所改善。因此,对OD或寡进展性疾病患者的治疗强化已成为一个备受关注和研究的领域。本文将综述寡转移、寡复发和寡进展性前列腺癌治疗背后的生物学、证据和争议。